Illumina, Inc. (NASDAQ:ILMN) Stake Lifted by Principal Securities Inc.

Principal Securities Inc. increased its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 38.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,728 shares of the life sciences company’s stock after buying an additional 483 shares during the quarter. Principal Securities Inc.’s holdings in Illumina were worth $231,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Versant Capital Management Inc grew its stake in Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after buying an additional 146 shares during the last quarter. Golden State Wealth Management LLC bought a new position in Illumina during the 4th quarter worth $32,000. TD Private Client Wealth LLC boosted its position in Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after acquiring an additional 141 shares during the period. V Square Quantitative Management LLC boosted its position in Illumina by 50.6% during the 4th quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company’s stock worth $52,000 after acquiring an additional 132 shares during the period. Finally, Private Trust Co. NA boosted its position in Illumina by 81.2% during the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after acquiring an additional 212 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ILMN has been the subject of a number of analyst reports. JPMorgan Chase & Co. boosted their price target on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Stephens boosted their price target on Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Royal Bank of Canada reduced their price target on Illumina from $250.00 to $247.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Canaccord Genuity Group reduced their price target on Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a research report on Friday, February 7th. Finally, TD Cowen lowered Illumina from a “buy” rating to a “hold” rating and reduced their price target for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $159.45.

Illumina Trading Down 3.1 %

Shares of NASDAQ ILMN opened at $94.20 on Monday. Illumina, Inc. has a 12 month low of $93.50 and a 12 month high of $156.66. The company has a market cap of $14.92 billion, a price-to-earnings ratio of -12.27, a P/E/G ratio of 1.60 and a beta of 1.10. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The business has a fifty day simple moving average of $127.98 and a 200-day simple moving average of $134.22.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Sell-side analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.